Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Artemisinin combination therapy for vivax malaria
Authors: Nicholas M. Douglas
Nicholas M. Anstey
Brian J. Angus
Francois Nosten
Ric N. Price
Menzies School of Health Research
Nuffield Department of Clinical Medicine
Royal Darwin Hospital
Shoklo Malaria Research Unit
Mahidol University
Keywords: Medicine
Issue Date: 1-Jun-2010
Citation: The Lancet Infectious Diseases. Vol.10, No.6 (2010), 405-416
Abstract: Early parasitological diagnosis and treatment with artemisinin-based combination therapies (ACTs) are key components of worldwide malaria elimination programmes. In general, use of ACTs has been limited to patients with falciparum malaria whereas blood-stage infections with Plasmodium vivax are mostly still treated with chloroquine. We review the evidence for the relative benefits and disadvantages of the existing separate treatment approach versus a unified ACT-based strategy for treating Plasmodium falciparum and P vivax infections in regions where both species are endemic (co-endemic). The separate treatment scenario is justifiable if P vivax remains sensitive to chloroquine and diagnostic tests reliably distinguish P vivax from P falciparum. However, with the high number of misdiagnoses in routine practice and the rise and spread of chloroquine-resistant P vivax, there might be a compelling rationale for a unified ACT-based strategy for vivax and falciparum malaria in all co-endemic regions. Analyses of the cost-effectiveness of ACTs for both Plasmodium species are needed to assess the role of these drugs in the control and elimination of vivax malaria. © 2010 Elsevier Ltd. All rights reserved.
ISSN: 14733099
Appears in Collections:Scopus 2006-2010

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.